Pfizer's bladder cancer therapy meets main goal in late-stage study
Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...
Armed robbery in Revesby5h
Pfizer's Sasanlimab Boosts Survival in Bladder Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational ...
FierceBiotech1d
Pfizer's PD-1 prospect beats age-old incumbent in phase 3 bladder cancer trial
Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...
BioSpace1d
Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
Pfizer Reveals Encouraging Data From Pivotal Bladder Cancer Trial
Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational ...
Pfizer's Sasanlimab Hits Late-Stage Study Primary Endpoint for Bladder Cancer
Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...
BioWorld18h
Pfizer’s PD-1 inhibitor hits endpoint in BCG-naïve bladder cancer
Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...
STAT1d
Intellia cuts 27% of staff, in the latest wave of gene-editing layoffs
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Pfizer study impact on CG Oncology to be minimal, says H.C. Wainwright
H.C. Wainwright analyst Andres Maldonado keeps a Buy rating on CG Oncology (CGON) with a $75 price target after Pfizer (PFE) announced positive ...
BioPharma Dive1d
Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets
Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...
Pfizer announces ‘positive’ results from Phase 3 CREST trial of sasanlimab
Pfizer (PFE) announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 ...
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, ...